November 24, 2016 - By Adrian Mccoy · 0 Comments
The stock of Amgen Incorporated (NASDAQ:AMGN) registered a decrease of 6.72% in short interest. AMGN’s total short interest was 7.38M shares in November as published by FINRA. Its down 6.72% from 7.91M shares, reported previously. With 4.70 million shares average volume, it will take short sellers 2 days to cover their AMGN’s short positions. The stock increased 0.48% or $0.7 on November 23, hitting $145.03. About 3.22 million shares traded hands. Amgen, Inc. (NASDAQ:AMGN) has declined 11.13% since April 22, 2016 and is downtrending. It has underperformed by 16.54% the S&P500.
Amgen Inc. is a biotechnology company. The company has a market cap of $106.99 billion. The Firm discovers, develops, makes and delivers various human therapeutics. It has a 14.49 P/E ratio. The Company’s business segment is human therapeutics.
Insitutional Activity: The institutional sentiment decreased to 1.26 in 2016 Q2. Its down 0.02, from 1.28 in 2016Q1. The ratio dived, as 56 funds sold all Amgen, Inc. shares owned while 422 reduced positions. 77 funds bought stakes while 533 increased positions. They now own 577.82 million shares or 7.76% less from 626.39 million shares in 2016Q1.
Cadence Capital Mgmt Limited Company has 80,878 shares for 0.93% of their US portfolio. Ray Gerald L Associates holds 2.96% or 121,816 shares in its portfolio. Conning last reported 0.94% of its portfolio in the stock. Old Mutual Customised Solutions (Proprietary) last reported 15,000 shares in the company. Bailard has 7,309 shares for 0.13% of their US portfolio. The New York-based F&V Cap Mngmt Ltd Liability Corp has invested 4.92% in Amgen, Inc. (NASDAQ:AMGN). Iridian Asset Mgmt Ct accumulated 0.04% or 25,000 shares. Motco last reported 259 shares in the company. Blume Mngmt accumulated 25 shares or 0.04% of the stock. Ssi Management, a California-based fund reported 2,637 shares. Investec Asset owns 2,293 shares or 0% of their US portfolio. South Dakota Council last reported 168,620 shares in the company. The California-based Van Strum And Towne has invested 4.08% in Amgen, Inc. (NASDAQ:AMGN). St Johns Investment Mngmt Ltd Limited Liability Company, a Florida-based fund reported 8,151 shares. Jacobus Wealth Mgmt holds 2,620 shares or 0.12% of its portfolio.
Insider Transactions: Since August 1, 2016, the stock had 0 insider purchases, and 1 insider sale for $523,758 net activity. $523,758 worth of shares were sold by Such Annette Louise on Monday, August 1.
Out of 17 analysts covering Amgen Inc. (NASDAQ:AMGN), 10 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 59% are positive. Amgen Inc. has been the topic of 29 analyst reports since August 3, 2015 according to StockzIntelligence Inc. The rating was maintained by RBC Capital Markets on Friday, July 31 with “Outperform”. As per Friday, August 21, the company rating was upgraded by Vetr. The rating was initiated by Raymond James on Tuesday, September 1 with “Market Perform”. The company was maintained on Friday, July 31 by Deutsche Bank. The firm earned “Buy” rating on Monday, February 8 by Argus Research. UBS maintained Amgen, Inc. (NASDAQ:AMGN) rating on Thursday, October 29. UBS has “Buy” rating and $180 price target. The stock of Amgen, Inc. (NASDAQ:AMGN) has “Neutral” rating given on Friday, July 29 by Citigroup. The stock has “Neutral” rating given by Citigroup on Thursday, February 25. The stock of Amgen, Inc. (NASDAQ:AMGN) has “Market Perform” rating given on Friday, December 4 by Wells Fargo. The firm earned “Market Perform” rating on Wednesday, June 29 by Bernstein.
Amgen Inc., incorporated on October 31, 1986, is a biotechnology company. The Firm discovers, develops, makes and delivers various human therapeutics. The Company’s business segment is human therapeutics. The Company’s marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine). The Firm focuses its research and development on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.
More notable recent Amgen, Inc. (NASDAQ:AMGN) news were published by: Fool.com which released: “Better Buy: Amgen Inc. vs. Johnson & Johnson” on November 08, 2016, also Fool.com with their article: “Why Amgen Inc. Shares Nose-Dived 15.4% in October” published on November 08, 2016, Fool.com published: “5 Things Amgen Inc.’s Management Wants You to Know” on October 28, 2016. More interesting news about Amgen, Inc. (NASDAQ:AMGN) were released by: Bloomberg.com and their article: “Amgen’s Repatha Unclogs Arteries in Good Sign for Future Sales” published on November 15, 2016 as well as Investorplace.com‘s news article titled: “3 Stocks to Watch on Wednesday: Amgen, Inc. (AMGN), Cisco Systems, Inc. (CSCO …” with publication date: November 17, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Adrian Mccoy